Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Improving type 2 diabetes management – evidence-based guidance for the use of SGLT2 inhibitors published inDiabetes Therapy

The Improving Diabetes Steering Committee
Posted on: 24 Jul 18

Cambridge, 23 July 2018 – The Improving Diabetes Steering Committeea group of leading diabetes specialists in the UKhas today published their first joint paper in Diabetes Therapy titled, ‘SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice’. The Committee came together to address priorities in improving the management of type 2 diabetes mellitus (T2DM), focusing on the place of the sodium-glucose co-transporter-2 inhibitor (SGLT2i) class of medicines, in the context of the current UK treatment pathway.

 

The published paper is a balanced review of the current evidence around the use of SGLT2is and addresses conflicting information that healthcare professionals have been given over time about the SGLT2i class and the appropriate place of these therapies within the T2DM treatment pathway. In developing this paper, the Committee wanted to address these issues by summarising current data and providing time-poor clinicians with clear, evidence-based guidance to help build confidence and understanding of this class of medications.  With this in mind, the Committee also included a benefit/risk tool, which summarises the information in the review, to support Primary Care clinicians in identifying the people most likely to benefit from SGLT2i treatments, as well as situations where caution may be required. 

 

Professor John Wilding (DM, FRCP) who leads diabetes and obesity research at the University of Liverpool, and is one of the co-authors of the paper said“helping to improve education in diabetes management is key to improving outcomes in the UK. As a committee, our focus was on providing balanced, accurate and evidence-based guidance to help clinicians identify those patients who would benefit most from the SGLT2i class of medicines.”

 

Dr Kevin Fernando (FRCGP, FRCP Edin. FAcadMEd MSc) GP Partner at North Berwick Health Centre, near Edinburghand co–author of the paper added“managing patients with type 2 diabetes is complex and can be challenging, particularly for clinicians working in Primary Care who are faced with many competing clinical priorities. We felt it was important to help provide every day, usable tools that will help healthcare professionals ensure their patients receive optimal care for their type 2 diabetes.”

The Improving Diabetes Steering Committee and the development of the SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice’, as well as the benefit/risk tool, are supported through funding from Napp Pharmaceuticals Ltd. Napp has reviewed this document for factual accuracy only.

 

To read the full paper and view the Benefit/Risk Tool, please visit https://link.springer.com/article/10.1007/s13300-018-0471-8

 

For further information on Napp and our work in diabetes, please contact:

Hanna Wikström

Communications Lead

hanna.wikstrom@napp.co.uk

01223 424444

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 24/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.